An insight into the future of medicine, including how the latest science is being used to better target diseases based on an individual’s genetics, biomarkers or lifestyle.
A closer look at the progress made so far on NHS England’s new national genomic medicine service.
Smaller, smarter and more sensitive — how four new technologies could change the way drugs are monitored and administered.
The 100,000 Genome Project is driving the move from a ‘one size fits all’ approach to treatment, towards personalised, or precision, medicine. Genetic information is also being used by pharmaceutical companies to help speed up drug discovery and development, and reduce the associated costs. Pharmacists will have an important role to play when genomic medicine goes mainstream.
Personalised treatment for depression on the horizon: predicting response to antidepressantsSubscription
Only one-third of patients with depression benefit from the first antidepressant they try, but researchers are striving to find biological features that predict how a person will respond to particular drugs so they can tailor treatment from the beginning.
Pharmacists must embrace pharmacogenetic services before other professions beat them to it Subscription
Multidisciplinary genetic testing services will help patients receive more targeted medicines, and pharmacists are the obvious healthcare professional to lead them.
Though commonplace in other countries, pharmacogenomic testing is yet to become a mainstay of NHS healthcare. Here, David Wright and Dhiren Bhatt argue how this process could improve the chance of therapeutic success and why pharmacists should be at the heart of its implementation.
Tsz To Sham encourages pharmacy students to take every opportunity to attend pharmacy conferences.
An overview of the anticancer agents that have been approved for use in the UK as part of a precision medicine approach for haematological malignancies, along with information relating to the relevant biomarkers and biomarker assays currently available.
An overview of the anticancer agents that have been approved for use in the UK as part of a precision medicine approach for solid tumours, along with information relating to the relevant biomarkers and biomarker assays currently available.
Conventional therapies and emergent precision medicines for cystic fibrosis: challenges and opportunitiesSubscription
Around 27 years ago, the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene – responsible for causing cystic fibrosis (CF) – marked a significant moment in the history of the condition. Despite the early promise of this target for gene therapy, a universally successful treatment has proven elusive in the ensuing years. While clinical trials involving gene therapy continue to make progress, the ‘magic bullet’ remains some way off. Survival continues to ...
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the process works.
Therapy needs to become more proactive and less “casualty-based” as more people live to an advanced age, Gino Martini, chief sceintist at the Royal Pharmaceutical Society has said.
Topics discussed at the Royal Pharmaceutical Society Science and Research Summit included possible medicines shortages in the event of a no-deal Brexit, tackling antimicrobial resistance and the challenges of implementing the Falsified Medicines Directive.